Calcitonin for Treating X-linked Hypophosphatemia
Diseases and Conditions Researched
Hypophosphatemic Rickets, X Linked Dominant
What is the purpose of this trial?
X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will:
- Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH.
- Evaluate whether nasal calcitonin improves serum phosphate levels in XLH.
- Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine.
- Make sure that nasal calcitonin is safe and well tolerated.
Click here for detailed participation information for this trial.
|Sponsors:||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Yale University|
|Dates:||July 23, 2012|
|Last Updated:||January 28, 2013|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.